Pipeline

February 29, 2020

Company	Drug/Device	Medical Condition	Status
Moderna	mRNA-1273	coronavirus	vials shipped to NIH for use in phase 1 trial
Magenta Therapeutics	MGTA-145	stem cell mobilization needed	completion of dosing in phase 1 trial
Pandion Therapeutics	PT101	autoimmune diseases	dosing of first subject in phase 1 trial
Actinium Pharmaceuticals	Actimab-A 7+3	acute myeloid leukemia	phase 1 trial dose escalation
Cyclo Therapeutics	Trappsol Cyclo	Niemann-Pick disease Type C Alzheimer’s disease	patient enrollment completed for phase 1 trial
Abivax	ABX196	inflammatory diseases, viral diseases and cancer	dosing of first patient in phase 1/2 trial
BeiGene SpringWorks (Mapkure)	BGB-3245	advanced or refractory solid tumors	initiation of phase 1 trial
Anokion	KAN-101	celiac disease	initiation of patient dosing in phase 1 trial
Neurimmune	NI006	ATTR cardiomyopathy	initiation of phase 1 trial
Inflazome	Somalix	harmful inflammation	completion of phase 1 trial
Sojournix	SJX-653	menopausal hot flashes	initiation of phase 2 trial
Ascentage Pharma	APG-1387	advanced pancreatic cancer	approval of phase 1/2b trial
CytomX Therapeutics Bristol-Myers Squibb	BMS-986249 alone and in combination with nivolumab	selected advanced solid tumors	initiated phase 2 expansion of phase 1/2a trial
Axcella	AXA1665-002	complex diseases	completed enrollment in phase 2 trial
Fulcrum Therapeutics	losmapimod	facioscapulohumeral muscular dystrophy	completed patient enrollment in phase 2b trial
iTeos Therapeutics	EOS-448	advanced cancers	enrolled first patient in phase 1/2 trial
Antibe Therapeutics	ATB-346	osteoarthritis pain	last patient enrolled in phase 2b trial
Exelixis	CABOMETYX (cabozantinib)	radioactive iodine-refractory differentiated thyroid cancer	phase 3 trial enrolling the first 100 of 300 patients at 150 sites globally
Marinus Pharmaceuticals	oral ganaxolone	CDKL5 Deficiency Disorder in children and young adults	phase 3 trial initiated enrolling 100 patients
Gilead Sciences	remdesivir	COVID-19	two phase 3 trials initiated
PolyPid	D-PLEX100	prevention of sternal wound infection after cardiac surgery	phase 3 trial initiated enrolling first patient
Noxopharm	Veyonda	soft tissue sarcomas	IND approved by the FDA
Translate Bio	MRT5005	cystic fibrosis	Fast-Track designation granted by the FDA
Debiopharm	Debio 1143	confirmed diagnosis of previously untreated, unresectable locally advanced squamous cell carcinoma of the head and neck	Breakthrough Therapy designation granted by the FDA
Lundbeck	VYEPTI (eptinezumab-jjmr)	migraine	approved by the FDA
Eli Lilly	Trulicity (dulaglutide)	major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors	new indication approved by the FDA
Seqirus	FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted)	seasonal influenza in individuals age 65 and older	approved by the FDA
Teva Respiratory	ArmonAir Digihaler (fluticasone propionate) Inhalation Powder)	asthma	approved by the FDA
Esperion	Nexletol (bempedoic acid)	adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C	approved by the FDA
Esperion	Nexlizet (bempedoic acid and ezetimibe)	adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C	approved by the FDA
Puma Biotechnology	neratinib in combination with capecitabine	adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting	supplemental NDA approved by the FDA
Acacia Pharma	BARHEMSY (amisulpride injection)	Postoperative Nausea and Vomiting	approved by the FDA